Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 9, 2016, Pages 3506-3515

  Kuhadiya, Nitesh D ^a   Ghanim, Husam ^a   Mehta, Aditya ^a   Garg, Manisha ^a   Khan, Salman ^a   Hejna, Jeanne ^a   Torre, Barrett ^a   Makdissi, Antoine ^a   Chaudhuri, Ajay ^a   Batra, Manav ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; DAPAGLIFLOZIN; FATTY ACID; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; KETONE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL LIPASE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING; WEAKNESS; WEIGHT REDUCTION; ADOLESCENT; ANALYSIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; FOLLOW UP; METABOLISM; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84988912446     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1451     Document Type: Article

References (20)

1. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84
2. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013;19:963-967
3. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 2014;37:210-216
4. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258-266
5. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual-cell function. Diabetes Care. 2011;34:1463-1468
6. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014;38:269-272
7. Kuhadiya ND, Dhindsa S, Ghanim H, et al. 2016 Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 39(6): 1027-1035
8. Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35:2198-2200
9. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes care. 2014;37:1480-1483
10. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17: 928-935
11. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412-419
12. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693
13. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38:2258-2265
14. Garg M, Kuhadiya ND, Ghanim H, Abuaysheh S, et al. Liraglutide acutely inhibits glucagon, lipolysis and ketogenesis in type 1 diabetes. Paper presented at: 98th Annual Meeting of The Endocrine Society; April 1-4, 2016; Boston
15. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Bode B, Beck RW, et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32: 2047-2049
16. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508
17. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849-2852
18. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014;37:666-670
19. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128
20. Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307:F317-F325